Figures computed from official regulatory filings — .
Ownershipinsiders 80.78% · institutions 0%
In EUR · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for TRANSGENE S.A. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Market information source · Oct 19, 2026
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| TSGH Société par actions simplifiée | Award | $145.8M | AMF |
| TSGH Société par actions simplifiée | Award | $35.7M | AMF |
| Hedi Ben Brahim | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 51First in 12mo | AMF |
| Alessandro RIVA | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 51First in 12mo | AMF |
| TSGH Société par actions simplifiée | Award | $29.8M | AMF |